ENDOVASC SPINS OFF ANTI-INFLAMATORY/CARDIOVASCULAR DRUG.

Endovasc Ltd., Inc. (OTCBB:ENVC), Montgomery, Texas, has announced that in accordance with its new business model, the company has established a new subsidiary, Liprostin(TM) Development Corporation, for its potential blockbuster anti-inflammatory/cardiovascular drug, Liprostin(TM). Liprostin will represent significant competition to Eli Lilly (NYSE: LLY) and Pfizer (NYSE: PFE), who both have similar drugs in the market. Liprostin is already approved for final FDA Phase III human clinical trials.

Liprostin(TM) is a liposomal prostaglandin-based treatment that can provide significant relief for people suffering from poor circulation due to arterial blockages, lack of blood to muscle tissues and heal intractable wounds. It improves diabetic conditions by increasing the pancreatic activity and reducing the need for insulin. The active agent in Liprostin(TM) (PGE-1) also improves liver and kidney function by stabilizing the cell membranes and protecting against free radical related damage to cells, and is as effective as dobutamine as a bridge to transplant.

Liprostin(TM) also may bring relief to millions of patients by preventing painful re-blockage of blood vessels in the heart. The drug may be locally delivered to angioplasty sites through the same catheters that are utilized for angioplasty or stent procedures. It is delivered directly into the vessel wall in a time-release form that can treat lesions over an extended period. Consequently, re-blockage of the blood vessel may be averted or greatly reduced, saving the health care system millions of dollars associated with the cost of a second procedure and the patient the ordeal of repeat surgical procedures.

Liprostin(TM) positively impacts many areas of treatment, such as angioplasty by inhibiting the migration of smooth muscle cells - the main culprit in re-blockage of blood vessels, and heart attacks by blocking platelet aggregation and thrombus formation. It benefits occlusive vascular diseases, ischemic ulcers, acts as critical limb salvage to prevent limb amputation, reduces the walking pain of claudicants, preserves the liver, and as a potent anti-inflammatory, reduces arthritic pain.

Based on the company's initial research, market potential for Liprostin(TM) is estimated to be $1.5 billion annually in the U.S. alone. The FDA has approved two indications of Liprostin(TM) for Phase III human clinical trials, including critical limb ischemia (prevention of amputation) and severe leg muscle pain due to poor circulation.

"This represents another big step in the execution of our new business model. As an independent subsidiary, it becomes increasingly easier for us to attract both financing and management talent necessary to take Liprostin(TM) through Phase III trials and to the market," said Dr. David P. Summers, CEO of Endovasc Ltd., Inc.

Any funding received by Liprostin(TM) Development Corporation will not dilute Endovasc stock, nor will it create debt for Endovasc. In the future, by board resolution, Endovasc shareholders of record will receive a distribution of stock, subject to the customary regulatory approvals and the filing of the necessary registration statement.

Endovasc's other products include Angiogenix(TM) -- the revolutionary new treatment that has shown to recruit the body's own stem cells that help grow new heart vessels to relieve chest pain and improve heart function, biodegradable stents, drug-delivery stents and newly discovered nutriceutical applications that may accelerate development of muscle mass and treat obesity in overweight diabetic women. Endovasc believes that its nutriceutical nicotine-based drinks, fitness bars or capsules (which, according to the company, will contain nicotine levels too low to be habituating or to cause the typical euphoria effects from smoking) combined with high protein complexes could become blockbuster nonprescription products, producing positive cash flow even sooner than its later stage drugs because they are not subject to the FDA approval process.

Endovasc Ltd., Inc., established in 1996, is a biotechnology company focused in the area of cardiovascular disease, pioneering drug delivery technology designed to deliver and release drugs to their intended targets in an efficient and controlled manner. The company's pipeline of products and processes include Liprostin(TM), ANGIOGENIX(TM), PROStent(TM) stent-coating technology, and a biodegradable resorbable stent prosthesis.

For more information, call 936/448-2222 or visit http://endovasc.com.